Extrait

This phase II trial is studying how well ziv-aflibercept works in treating patients with locally advanced, unresectable or metastatic gynecologic soft tissue sarcoma. Ziv-aflibercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Critère d'inclusion

• Fallopian Tube Cancer,Female Reproductive Cancer,Ovarian Carcinosarcoma,Ovarian Sarcoma,Recurrent Ovarian Epithelial Cancer,Recurrent Uterine Sarcoma,Stage III Ovarian Epithelial Cancer,Stage III Uterine Sarcoma,Stage IV Ovarian Epithelial Cancer,Stage IV Uterine Sarcoma,uterine carcinosarcoma,Uterine Leiomyosarcoma

Liens

• ictrp
• nct